84908-3  Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:  

PANEL HIERARCHY  (view this panel in the LForms viewer)

  LOINC#   LOINC Name R/O/C  Cardinality  Ex. UCUM Units 
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:    
       46106-1   Medical record numberMedical record numberMedical record number: ID: Pt: ^Patient: Nom:    
       45397-7   Medicare or comparable numberMedicare or comparable numberMedicare or comparable number: ID: Pt: ^Patient: Nom:    
       42071-1   Accession number and class of case and sequence number override flag Cancer caseAccession number and class of case and sequence number override flag Cancer caseAccession number & class of case & sequence number override flag: Arb: Pt: Cancer case.XXX: Ord:    
       63907-0   Clinician-diagnosed illness [PhenX]Clinician-diagnosed illness [PhenX]Clinician-diagnosed illness: Find: Pt: ^Patient: Nom: PhenX    
       29306-8   Surgery procedureSurgery procedureSurgery procedure: Type: Pt: ^Patient: Nom:    
       2857-1   Prostate specific Ag [Mass/​volume] in Serum or PlasmaProstate specific Ag [Mass/​volume] in Serum or PlasmaProstate specific Ag: MCnc: Pt: Ser/​Plas: Qn:   ng/mL 
       55752-0   Clinical informationClinical informationClinical information: Find: Pt: ^Patient: Nar:    
       21908-9   Stage group.clinical CancerStage group.clinical CancerStage group.clinical: Class: Pt: Cancer.XXX: Nom:    
       33723-8   Specimen lengthSpecimen lengthSpecimen length: Len: Pt: Specimen: Qn:   cm 
       84894-5   Dimension [Length] of SpecimenDimension [Length] of SpecimenDimension: Len: Pt: Specimen: Qn:   mm 
       84895-2   Seminal vesicles [Presence] in SpecimenSeminal vesicles [Presence] in SpecimenSeminal vesicles: PrThr: Pt: Specimen: Ord:    
       84896-0   Lymph node(s) [Presence] in SpecimenLymph node(s) [Presence] in SpecimenLymph node(s): PrThr: Pt: Specimen: Ord:    
       84897-8   Dominant nodule quadrant [Anatomy] in Prostate tumorDominant nodule quadrant [Anatomy] in Prostate tumorDominant nodule quadrant: Anat: Pt: Prostate tumor: Nom:    
       84898-6   Dominant nodule plane [Anatomy] in Prostate tumorDominant nodule plane [Anatomy] in Prostate tumorDominant nodule plane: Anat: Pt: Prostate tumor: Nom:    
       84899-4   Other nodules greater than 10mm in diameter [Presence] in Prostate tumorOther nodules greater than 10mm in diameter [Presence] in Prostate tumorOther nodules greater than 10mm in diameter: PrThr: Pt: Prostate tumor: Ord:    
       84900-0   Other nodule quadrant [Anatomy] in Prostate tumorOther nodule quadrant [Anatomy] in Prostate tumorOther nodule quadrant: Anat: Pt: Prostate tumor: Nom:    
       84901-8   Other nodule plane [Anatomy] in Prostate tumorOther nodule plane [Anatomy] in Prostate tumorOther nodule plane: Anat: Pt: Prostate tumor: Nom:    
       44657-5   Dominant nodule.maximum.dimension in Prostate tumorDominant nodule.maximum.dimension in Prostate tumorDominant nodule.max.dimension: Len: Pt: Prostate tumor: Qn:   cm 
       44654-2   Tissue involved by tumor in Prostate tumorTissue involved by tumor in Prostate tumorProstatic tissue involved by tumor: NFr: Pt: Prostate tumor: Qn:  
       35266-6   Gleason score in Specimen QualitativeGleason score in Specimen QualitativeGleason score: Score: Pt: Specimen: Ord:   {score} 
       84903-4   Extraprostatic extension extent [Type] of Prostate tumorExtraprostatic extension extent [Type] of Prostate tumorExtraprostatic extension extent: Type: Pt: Prostate tumor: Ord:    
       84902-6   Extraprostatic extension site [Anatomy] of Prostate tumorExtraprostatic extension site [Anatomy] of Prostate tumorExtraprostatic extension site: Anat: Pt: Prostate tumor: Nom:    
       81168-7   Site of adjacent organ or tissue involvement Cancer specimenSite of adjacent organ or tissue involvement Cancer specimenSite of adjacent organ or tissue involvement: Anat: Pt: Cancer specimen: Nom:    
       44654-2   Tissue involved by tumor in Prostate tumorTissue involved by tumor in Prostate tumorProstatic tissue involved by tumor: NFr: Pt: Prostate tumor: Qn:  
       84904-2   Gleason score at positive margin in Prostate tumor QualitativeGleason score at positive margin in Prostate tumor QualitativeGleason score at positive margin: Score: Pt: Prostate tumor: Ord:    
       84905-9   Margin involvement [Type] in Prostate tumorMargin involvement [Type] in Prostate tumorMargin involvement: Type: Pt: Prostate tumor: Nom:    
       84895-2   Seminal vesicles [Presence] in SpecimenSeminal vesicles [Presence] in SpecimenSeminal vesicles: PrThr: Pt: Specimen: Ord:    
       84906-7   Bladder neck involvement of Prostate tumorBladder neck involvement of Prostate tumorBladder neck involvement: PrThr: Pt: Prostate tumor: Ord:    
 

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Cancer pathology panel  Pt  Prostate cancer.XXX 
  Long Common Name:  Cancer pathology panel - Prostate cancer
  Shortname:  Cancer Path Pnl Prostate cancer

TERM DEFINITION/DESCRIPTION(S)
  This panel is for reporting relevant pathological information for prostate cancers.
 
 

BASIC ATTRIBUTES
  Class/Type: PANEL.PATH/Lab
  Panel Type: Panel
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Order
  Status: Trial – caution, may change

PARTS

Part Type    Part No.  Part Name   
Component   LP207911-1  Cancer pathology panel 
Property   LP6769-6 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP7502-0  Prostate cancer.XXX   [Prostate cancer XXX] 
Scale   LP7747-1 
Fragments for synonyms   LP21059-8  Panel 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  癌症病理学组套:  -:  时间点:  前列腺癌.XXX:  -:  癌症病理学组套:  -:  时间点:  前列腺癌.XXX:  -:  癌症病理学组套:  -:  时间点:  前列腺癌.XXX:  -:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Patologia cancro panel:  -:  Pt:  Prostata, cancro.XXX:  -:  Patologia cancro panel:  -:  Pt:  Prostata, cancro.XXX:  -:  Patologia cancro panel:  -:  Pt:  Prostata, cancro.XXX:  -:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Perfil de patología neoplásica:  Propiedades mixtas (sólo paneles):  Punto temporal:  Cáncer de próstata.XXX:  -:  Perfil de patología neoplásica:  Propiedades mixtas (sólo paneles):  Punto temporal:  Cáncer de próstata.XXX:  -:  Perfil de patología neoplásica:  Propiedades mixtas (sólo paneles):  Punto temporal:  Cáncer de próstata.XXX:  -:  

RELATED NAMES
  CA PANEL.PATH Prost
  Cancer Path Pnl Panl Prostatic
  Misc Path Random
  Miscellaneous Pathology To be specified in another part of the message
  Other Pnl Unspecified
  Pan Point in time  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Cancer pathology panel - Prostate cancer
  Shortname: Cancer Path Pnl Prostate cancer
  Fully Specified Name: Cancer pathology panel: -: Pt: Prostate cancer.XXX: -:
     
  Component Word Count: 0
  ID: 90078
  # of Panel Elements: 29
  Status (Raw): TRIAL



Selected information about each LOINC that is part of this panel



46106-1   Medical record numberMedical record numberMedical record number: ID: Pt: ^Patient: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Medical record number  ID  Pt  ^Patient  Nom 
  Long Common Name:  Medical record number

BASIC ATTRIBUTES
  Class/Type: SURVEY.MDS/Survey
  First Released in Version: 2.17
  Last Updated in Version: 2.48
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Removed method of MDS and copyright information since this is not an MDS-specific concept. Also change scale from narrative to nominal since this is not a narrative concept.

HL7 ATTRIBUTES
  HL7 Field ID: PID-3

MEMBER OF THESE PANELS
  45981-8   MDS full assessment form - version 2.0MDS full assessment form - version 2.0MDS full assessment form - version 2.0: -: Pt: ^Patient: -:
  46102-0   MDS quarterly assessment form - version 2.0MDS quarterly assessment form - version 2.0MDS quarterly assessment form - version 2.0: -: Pt: ^Patient: -:
  46103-8   MDS quarterly assessment form - version 2.0 - optional version for RUG-IIIMDS quarterly assessment form - version 2.0 - optional version for RUG-IIIMDS quarterly assessment form - version 2.0 - optional version for RUG-III: -: Pt: ^Patient: -:
  46104-6   MDS quarterly assessment form - version 2.0 - optional version for RUG-III 1997 updateMDS quarterly assessment form - version 2.0 - optional version for RUG-III 1997 updateMDS quarterly assessment form - version 2.0 - optional version for RUG-III 1997 update: -: Pt: ^Patient: -:
  54580-6   Minimum Data Set - version 3.0Minimum Data Set - version 3.0Minimum Data Set - version 3.0: -: Pt: ^Patient: -:
  62949-3   PhenX domain - GastrointestinalPhenX domain - GastrointestinalPhenX domain - Gastrointestinal: -: Pt: ^Patient: -: PhenX
  74495-3   Patient safety event report - hospital - healthcare event reporting form (HERF) - version 1.2 [AHRQ]Patient safety event report - hospital - healthcare event reporting form (HERF) - version 1.2 [AHRQ]Patient safety event report - hospital - healthcare event reporting form - version 1.2: -: Pt: ^Patient: -: AHRQ
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP75102-1  Medical record number 
Property   LP6818-1  ID   [Identifier] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7750-5  Nom 

RELATED NAMES
  Ident No Random
  Identifier Nominal SURVEY.MDS
  Medical record no. Num  
  MRN Point in time  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Medical record number
  Fully Specified Name: Medical record number: ID: Pt: ^Patient: Nom:
     
  Component Word Count: 3
  ID: 39511
  Status (Raw): ACTIVE


45397-7   Medicare or comparable numberMedicare or comparable numberMedicare or comparable number: ID: Pt: ^Patient: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Medicare or comparable number  ID  Pt  ^Patient  Nom 
  Long Common Name:  Medicare or comparable number
  Shortname:  Medicare or comparable #

BASIC ATTRIBUTES
  Class/Type: ADMIN/Clinical
  First Released in Version: 2.17
  Last Updated in Version: 2.61
  Status: Active.
Change Reason: Changed CLASS to ADMIN.

HL7 ATTRIBUTES
  HL7 Field ID: PID-3

MEMBER OF THESE PANELS
  45963-6   MDS basic assessment tracking form - version 2.0MDS basic assessment tracking form - version 2.0MDS basic assessment tracking form - version 2.0: -: Pt: ^Patient: -:
  46462-8   Outcome and assessment information set (OASIS) form - version B1Outcome and assessment information set (OASIS) form - version B1Outcome and assessment information set (OASIS) form - version B1: -: Pt: ^Patient: -:
  52743-2   Continuity Assessment Record and Evaluation (CARE) tool - Acute CareContinuity Assessment Record and Evaluation (CARE) tool - Acute CareContinuity assessment record and evaluation tool - Acute care: -: Pt: ^Patient: -: CARE
  52744-0   Continuity Assessment Record and Evaluation (CARE) tool - Post Acute Care (PAC) - AdmissionContinuity Assessment Record and Evaluation (CARE) tool - Post Acute Care (PAC) - AdmissionContinuity assessment record and evaluation tool - Post acute care - admission: -: Pt: ^Patient: -: CARE
  52745-7   Continuity Assessment Record and Evaluation (CARE) tool - Post Acute Care (PAC) - DischargeContinuity Assessment Record and Evaluation (CARE) tool - Post Acute Care (PAC) - DischargeContinuity assessment record and evaluation tool - Post acute care - discharge: -: Pt: ^Patient: -: CARE
  52746-5   Continuity Assessment Record and Evaluation (CARE) tool - InterimContinuity Assessment Record and Evaluation (CARE) tool - InterimContinuity assessment record and evaluation tool - Interim: -: Pt: ^Patient: -: CARE
  52747-3   Continuity Assessment Record and Evaluation (CARE) tool - ExpiredContinuity Assessment Record and Evaluation (CARE) tool - ExpiredContinuity assessment record and evaluation tool - Expired: -: Pt: ^Patient: -: CARE
  52748-1   Continuity Assessment Record and Evaluation (CARE) tool - Home Health AdmissionContinuity Assessment Record and Evaluation (CARE) tool - Home Health AdmissionContinuity assessment record and evaluation tool - Home health admission: -: Pt: ^Patient: -: CARE
  54580-6   Minimum Data Set - version 3.0Minimum Data Set - version 3.0Minimum Data Set - version 3.0: -: Pt: ^Patient: -:
  57039-0   Outcome and assessment information set (OASIS) form - version COutcome and assessment information set (OASIS) form - version COutcome and assessment information set (OASIS) form - version C: -: Pt: ^Patient: -:
  57190-1   Outcome and assessment information set (OASIS) form - version C - Start of careOutcome and assessment information set (OASIS) form - version C - Start of careOutcome and assessment information set (OASIS) form - version C - Start of care: -: Pt: ^Patient: -:
  67868-0   End Stage Renal Disease (ESRD) Medical Evidence Report, Medicare Entitlement AndOr Patient Registration - OMB CMS form 2728End Stage Renal Disease (ESRD) Medical Evidence Report, Medicare Entitlement AndOr Patient Registration - OMB CMS form 2728End stage renal disease medical evidence report, medicare entitlement &or patient registration - OMB CMS form 2728: -: Pt: ^Patient: -:
  68359-9   End Stage Renal Disease (ESRD) Death Notification - OMB CMS form 2746End Stage Renal Disease (ESRD) Death Notification - OMB CMS form 2746End stage renal disease death notification - OMB CMS form 2746: -: Pt: ^Patient: -:
  69412-5   Continuity Assessment Record and Evaluation (CARE) tool - Long term care hospital (LTCH) - version 1.0Continuity Assessment Record and Evaluation (CARE) tool - Long term care hospital (LTCH) - version 1.0Continuity assessment record and evaluation tool - long term care hospital - version 1.0: -: Pt: ^Patient: -: CARE
  70297-7   ESRD patient information panelESRD patient information panelPatient information panel: -: Pt: ^Patient: -: ESRD
  83265-9   Inpatient Rehabilitation Facility - Patient Assessment Instrument (IRF-PAI) - version 1.4 [CMS Assessment]Inpatient Rehabilitation Facility - Patient Assessment Instrument (IRF-PAI) - version 1.4 [CMS Assessment]Inpatient Rehabilitation Facility - Patient Assessment Instrument - version 1.4: -: Pt: ^Patient: -: CMS Assessment
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:
  85654-2   Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - version 3.00 [CMS Assessment]Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - version 3.00 [CMS Assessment]Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - version 3.00: -: Pt: ^Patient: -: CMS Assessment

PARTS

Part Type    Part No.  Part Name   
Component   LP75106-2  Medicare or comparable number 
Property   LP6818-1  ID   [Identifier] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7750-5  Nom 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  医疗保险或类似编号:  标识符:  时间点:  ^患者:  名义型:  医疗保险或类似编号:  标识符:  时间点:  ^患者:  名义型:  医疗保险或类似编号:  标识符:  时间点:  ^患者:  名义型:  

RELATED NAMES
  ADMIN Medicare or comparable # Num
  Ident No Point in time
  Identifier Nominal Random

ALTERNATIVE CODES
  CMS: 
  CMS:  A0600B 

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Medicare or comparable number
  Shortname: Medicare or comparable #
  Fully Specified Name: Medicare or comparable number: ID: Pt: ^Patient: Nom:
     
  Component Word Count: 4
  ID: 38746
  Status (Raw): ACTIVE


42071-1   Accession number and class of case and sequence number override flag Cancer caseAccession number and class of case and sequence number override flag Cancer caseAccession number & class of case & sequence number override flag: Arb: Pt: Cancer case.XXX: Ord:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Accession number & class of case & sequence number override flag  Arb  Pt  Cancer case.XXX  Ord 
  Long Common Name:  Accession number and class of case and sequence number override flag Cancer case
  Shortname:  Ascn/class/seq O/R Cancer case

TERM DEFINITION/DESCRIPTION(S)
  Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edit in the NAACCR Metafile of the EDITS software:
Accession Number, Class of Case, Seq Number (COC)... NAACCR Data Standards and Data Dictionary Version 11
 
 

BASIC ATTRIBUTES
  Class/Type: TUMRRGT/Clinical
  First Released in Version: 2.16
  Last Updated in Version: 2.38
  Status: Active

NORMATIVE ANSWER LIST    (LL152-0)  
 
Source: 
  SEQ#        Answer        Code         Answer ID    
  1       Reviewed       1       LA4354-2  
  2       Not reviewed       Blank       LA4694-1  

MEMBER OF THESE PANELS
  49083-9   North American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 11 panelNorth American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 11 panelNorth American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 11 panel: -: Pt: ^Patient: -:
  59852-4   North American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 12 panelNorth American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 12 panelNorth American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 12 panel: -: Pt: ^Patient: -:
  84907-5   Cancer pathology panel - Colorectal cancer specimenCancer pathology panel - Colorectal cancer specimenCancer pathology panel: -: Pt: Colorectal cancer specimen: -:
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP71998-6  Accession number & class of case & sequence number override flag   [Accession number and class of case and sequence number override flag] 
Property   LP6781-1  Arb   [Arbitrary] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP7100-3  Cancer case.XXX   [Cancer case XXX] 
Scale   LP7751-3  Ord 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  登录号与案例类别与序号重写标志:  任意型:  时间点:  癌症病例.XXX:  序数型:  登录号与案例类别与序号重写标志:  任意型:  时间点:  癌症病例.XXX:  序数型:  登录号与案例类别与序号重写标志:  任意型:  时间点:  癌症病例.XXX:  序数型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Numero di ammissione & classe di caso & numero di sequenza, flag ignorato:  Arb:  Pt:  Cancro, caso.XXX:  Ord:  Numero di ammissione & classe di caso & numero di sequenza, flag ignorato:  Arb:  Pt:  Cancro, caso.XXX:  Ord:  Numero di ammissione & classe di caso & numero di sequenza, flag ignorato:  Arb:  Pt:  Cancro, caso.XXX:  Ord:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Инвентарный номер & класс случая & порядковый номер переопределение флаг:  Произв:  ТчкВрм:  Рак случай.XXX:  Пор:  Инвентарный номер & класс случая & порядковый номер переопределение флаг:  Произв:  ТчкВрм:  Рак случай.XXX:  Пор:  Инвентарный номер & класс случая & порядковый номер переопределение флаг:  Произв:  ТчкВрм:  Рак случай.XXX:  Пор:  

RELATED NAMES
  Arbitrary Ordinal Screen
  Ascn/class/seq O/R Other To be specified in another part of the message
  CA Point in time TUMOR REGISTRY(NAACCR)
  Misc QL Unspecified
  Miscellaneous Qual  
  No Qualitative  
  Num Random  

ALTERNATIVE CODES
  NAACCR_ID:  1985 

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Accession number and class of case and sequence number override flag Cancer case
  Shortname: Ascn/class/seq O/R Cancer case
  Fully Specified Name: Accession number & class of case & sequence number override flag: Arb: Pt: Cancer case.XXX: Ord:
     
  Component Word Count: 9
  ID: 35004
  Status (Raw): ACTIVE


63907-0   Clinician-diagnosed illness [PhenX]Clinician-diagnosed illness [PhenX]Clinician-diagnosed illness: Find: Pt: ^Patient: Nom: PhenX  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Clinician-diagnosed illness  Find  Pt  ^Patient  Nom  PhenX
  Long Common Name:  Clinician-diagnosed illness [PhenX]
  Shortname:  Clinician-diagnosed illness PhenX

BASIC ATTRIBUTES
  Class/Type: PHENX/Clinical
  First Released in Version: 2.36
  Last Updated in Version: 2.44
  Status: Trial – caution, may change

NORMATIVE ANSWER LIST    (LL1116-4)  
 
Source: Consensus measures for Phenotypes and Exposures
  SEQ#        Answer        Code         Answer ID    
  1       Myocardial infarction       1       LA14274-7  
  2       Angina pectoris       2       LA14275-4  
  3       Coronary bypass       3       LA14276-2  
  4       Angioplasty or stent       4       LA14277-0  
  5       Transient ischemic attack - TIA       5       LA14278-8  
  6       Stroke (CVA) or TIA       6       LA12362-2  
  7       Deep vein thrombosis       7       LA7425-7  
  8       Pulmonary embolism       8       LA7468-7  
  9       Melanoma       9       LA14279-6  
  10       Basal cell skin cancer       10       LA14280-4  
  11       Squamous cell (epidermoid) carcinoma       11       LA15445-2  
  12       Fibrocystic or other benign breast disease       12       LA14282-0  
  13       Breast cancer       13       LA14283-8  
  14       Other cancer       14       LA14284-6  
  15       Colon or rectal polyp - benign       15       LA14285-3  
  16       Ulcerative colitis or Crohn’s       16       LA14286-1  
  17       Gastric or duodenal ulcer       17       LA14287-9  
  18       Barrett’s Esophagus       18       LA14288-7  
  19       Gallstones       19       LA14289-5  
  20       Cholecystectomy       20       LA14290-3  
  21       Diabetes mellitus       21       LA14291-1  
  22       Elevated cholesterol       22       LA14292-9  
  23       High blood pressure       23       LA14293-7  
  24       Endometriosis - 1st diagnosis       24       LA14294-5  
  25       Uterine fibroids - 1st diagnosis       25       LA14295-2  
  26       Premenstrual syndrome - PMS       26       LA14296-0  
  27       Kidney stones       27       LA14297-8  
  28       Multiple Sclerosis       28       LA14298-6  
  29       Asthma, doctor diagnosed       29       LA14299-4  
  30       Emphysema or chronic bronchitis, doctor diagnosis       30       LA14300-0  
  31       Pneumonia, x-ray confirmed       31       LA14301-8  
  32       Graves’ Disease - hyperthyroidism       32       LA14302-6  
  33       Hypothyroidism       33       LA14303-4  
  34       Thyroid nodule (benign)       34       LA14304-2  
  35       Gout       35       LA14305-9  
  36       SLE (systemic lupus)       36       LA14306-7  
  37       Rheumatoid arthritis, doctor diagnosis       37       LA14307-5  
  38       Other arthritis       38       LA14308-3  
  39       Depression, clinician diagnosis       39       LA14309-1  
  40       Other major illness or surgery       40       LA14310-9  

SURVEY QUESTION
Source: PhenX.070801010000

MEMBER OF THESE PANELS
  62557-4   PhenX domain - CancerPhenX domain - CancerPhenX domain - Cancer: -: Pt: ^Patient: -: PhenX
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP114934-5  Clinician-diagnosed illness 
Property   LP6813-2  Find   [Finding] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7750-5  Nom 
Method   LP95333-8  PhenX 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  临床医师诊断的疾病:  发现:  时间点:  ^患者:  名义型:  PhenX临床医师诊断的疾病:  发现:  时间点:  ^患者:  名义型:  PhenX临床医师诊断的疾病:  发现:  时间点:  ^患者:  名义型:  PhenX
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Клинически-диагностированное заболевание:  Находка:  ТчкВрм:  ^Пациент:  Ном:  PhenXКлинически-диагностированное заболевание:  Находка:  ТчкВрм:  ^Пациент:  Ном:  PhenXКлинически-диагностированное заболевание:  Находка:  ТчкВрм:  ^Пациент:  Ном:  PhenX

RELATED NAMES
  Finding Point in time  
  Findings Random  
  Nominal    

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Clinician-diagnosed illness [PhenX]
  Shortname: Clinician-diagnosed illness PhenX
  Fully Specified Name: Clinician-diagnosed illness: Find: Pt: ^Patient: Nom: PhenX
     
  Component Word Count: 3
  ID: 59289
  Status (Raw): TRIAL


29306-8   Surgery procedureSurgery procedureSurgery procedure: Type: Pt: ^Patient: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Surgery procedure  Type  Pt  ^Patient  Nom 
  Long Common Name:  Surgery procedure
  Shortname:  Surgery procedure

BASIC ATTRIBUTES
  Class/Type: H&P.PX/Clinical
  First Released in Version: 2.03
  Last Updated in Version: 2.29
  Status: Active

EXAMPLE ANSWERS
  Subset of SNOMED P-codes

MEMBER OF THESE PANELS
  55168-9   Data Elements for Emergency Department Systems (DEEDS) Release 1.1Data Elements for Emergency Department Systems (DEEDS) Release 1.1Data Elements for Emergency Department Systems (DEEDS) Release 1.1: -: Pt: ^Patient: -:
  55169-7   Data Elements for Emergency Department Systems (DEEDS) Release 1.0Data Elements for Emergency Department Systems (DEEDS) Release 1.0Data Elements for Emergency Department Systems (DEEDS) Release 1.0: -: Pt: ^Patient: -:
  62863-6   PhenX domain - Infectious diseases and immunityPhenX domain - Infectious diseases and immunityPhenX domain - Infectious diseases and immunity: -: Pt: ^Patient: -: PhenX
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP73443-1  Surgery procedure 
Property   LP6886-8  Type 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7750-5  Nom 
Fragments for synonyms   LP75922-2  P' 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  外科手术操作:  类型:  时间点:  ^患者:  名义型:  外科手术操作:  类型:  时间点:  ^患者:  名义型:  外科手术操作:  类型:  时间点:  ^患者:  名义型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Procedura chirurgica:  Tipo:  Pt:  ^Paziente:  Nom:  Procedura chirurgica:  Tipo:  Pt:  ^Paziente:  Nom:  Procedura chirurgica:  Tipo:  Pt:  ^Paziente:  Nom:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Surgery procedureProcedimento cirúrgico:  Tipo:  Pt:  ^Paciente:  Nom:  Procedimento cirúrgico:  Tipo:  Pt:  ^Paciente:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Хирургическое вмешательство:  Тип:  ТчкВрм:  ^Пациент:  Ном:  Хирургическое вмешательство:  Тип:  ТчкВрм:  ^Пациент:  Ном:  Хирургическое вмешательство:  Тип:  ТчкВрм:  ^Пациент:  Ном:  
  Spanish (ARGENTINA)  (From: Conceptum Medical Terminology Center)
 
  procedimiento quirúrgico:tipo:punto en el tiempo:^paciente:Nominal:procedimiento quirúrgico:  tipo:  punto en el tiempo:  ^paciente:  Nominal:  procedimiento quirúrgico:  tipo:  punto en el tiempo:  ^paciente:  Nominal:  

RELATED NAMES
  H+P P prime Surg
  H+P.PX Point in time Typ
  Nominal Random  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Surgery procedure
  Shortname: Surgery procedure
  Fully Specified Name: Surgery procedure: Type: Pt: ^Patient: Nom:
     
  Component Word Count: 2
  ID: 21062
  Status (Raw): ACTIVE


2857-1   Prostate specific Ag [Mass/​volume] in Serum or PlasmaProstate specific Ag [Mass/​volume] in Serum or PlasmaProstate specific Ag: MCnc: Pt: Ser/​Plas: Qn:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Prostate specific Ag  MCnc  Pt  Ser/Plas  Qn 
  Consumer Name:  PSA serum/plasma
  Long Common Name:  Prostate specific Ag [Mass/volume] in Serum or Plasma
  Shortname:  PSA SerPl-mCnc

PART DEFINITION/DESCRIPTION(S)
  Part: Prostate specific Ag
  Prostate-specific antigen is a glycoprotein and occurs in three forms in the blood: 1) PSA complexed with the serine protease inhibitor or alpha-1-antichymotrypsin, 2) free or uncomplexed PSA, and 3) PSA complexed with alpha-2 macroglobulin. The first two are detectable and the third is undectectable in conventional immunoassay. Elevated levels of PSA in serum or plasma indicate a pathological condition of the prostate (e.g. carcinoma, benign prostatic hyperplasia (BPH), or prostatitis). Inflammation or trauma to the prostate, such as following a biopsy or colonoscopy, can result in PSA elevations. PSA levels are also checked to monitor therapy in patients with prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: CHEM/Lab
  CDISC Lab Test: Y
  Common Lab Results Rank: #124
  Common SI Lab Results Rank: #124
  Common Orders Rank: #122
  First Released in Version: 1.0
  Last Updated in Version: 2.61
  Mass or Substance Property: M
  Order vs. Obs.: Both
  Status: Active

MEMBER OF THESE PANELS
  53764-7   Prostate specific Ag panel - Serum or PlasmaProstate specific Ag panel - Serum or PlasmaProstate specific Ag panel: -: Pt: Ser/​Plas: -:
  75868-0   HEDIS 2015 Value SetsHEDIS 2015 Value SetsHEDIS 2015 Value Sets: -: Pt: ^Patient: -:
  79544-3   HEDIS 2016 Value SetsHEDIS 2016 Value SetsHEDIS 2016 Value Sets: -: Pt: ^Patient: -:
  82955-6   HEDIS 2017 Value SetsHEDIS 2017 Value SetsHEDIS 2017 Value Sets: -: Pt: ^Patient: -:
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP18193-0  Prostate specific Ag 
Component   LP14689-1  Prostate specific 
     Suffix   LP20666-1  Ag 
Property   LP6827-2  MCnc   [Mass Concentration] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP7576-4  Ser/Plas   [Serum or Plasma] 
Scale   LP7753-9  Qn 
Fragments for synonyms   LP28586-3  Specific 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  前列腺特异性 抗原:  质量浓度:  时间点:  血清/​血浆:  定量型:  前列腺特异性 抗原:  质量浓度:  时间点:  血清/​血浆:  定量型:  前列腺特异性 抗原:  质量浓度:  时间点:  血清/​血浆:  定量型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Prostaatspecifiek Ag:  Massa concentratie:  Moment:  Serum of plasma:  Kwantitatief:  Prostaatspecifiek Ag:  Massa concentratie:  Moment:  Serum of plasma:  Kwantitatief:  Prostaatspecifiek Ag:  Massa concentratie:  Moment:  Serum of plasma:  Kwantitatief:  
  French (BELGIUM)  (From: Regenstrief-generated full translation based on part translation provided by Jean M. Prevost, MD, Biopathology)
 
  Spécifique de la prostate Ag:  Concentration de masse:  Temps ponctuel:  Sérum/​Plasma:  Quantitatif:  Spécifique de la prostate Ag:  Concentration de masse:  Temps ponctuel:  Sérum/​Plasma:  Quantitatif:  Spécifique de la prostate Ag:  Concentration de masse:  Temps ponctuel:  Sérum/​Plasma:  Quantitatif:  
  French (CANADA)  (From: Regenstrief-generated full translation based on part translation provided by Canada Health Infoway Inc.)
 
  Spécifique à la prostate , Ag:  Concentration de masse:  Temps ponctuel:  Sérum/​Plasma:  Quantitatif:  Spécifique à la prostate , Ag:  Concentration de masse:  Temps ponctuel:  Sérum/​Plasma:  Quantitatif:  Spécifique à la prostate , Ag:  Concentration de masse:  Temps ponctuel:  Sérum/​Plasma:  Quantitatif:  
  French (FRANCE)  (From: ASIP Santé (Agence des systèmes d'information partagés de santé))
 
  Prostate spécifique antigène:  Masse/​Volume:  Ponctuel:  Sérum/​Plasma:  Numérique:  Prostate spécifique antigène:  Masse/​Volume:  Ponctuel:  Sérum/​Plasma:  Numérique:  Prostate spécifique antigène:  Masse/​Volume:  Ponctuel:  Sérum/​Plasma:  Numérique:  
  French (SWITZERLAND)  (From: CUMUL, Switzerland)
 
  S--prostate, antigène spécifiqueS--prostate, antigène spécifiqueS--prostate, antigène spécifique
  German (GERMANY)  (From: Institute for Medical Documentation and Information (DIMDI))
 
  Prostata-spezifisches Ag:  MKnz:  Pkt:  Ser/​Plas:  Qn:  Prostata-spezifisches Ag:  MKnz:  Pkt:  Ser/​Plas:  Qn:  Prostata-spezifisches Ag:  MKnz:  Pkt:  Ser/​Plas:  Qn:  
  German (SWITZERLAND)  (From: CUMUL, Switzerland)
 
  S--Prostataspezifisch AntigenS--Prostataspezifisch AntigenS--Prostataspezifisch Antigen
  Greek (GREECE)  (From: Regenstrief-generated full translation based on part translation provided by Efstratia Kontaxi, MD, MSc, and Evripidis Stefanidis, MD, with technical support from Panagiotis Kontaxis, Diploma of Electrical and Computer Engineering.)
 
  Ειδικό προστατικό Αντιγόνο:  Συγκέντρωση μάζας:  Χρονική στιγμή:  Ορός/​Πλάσμα:  Ποσοτική:  Ειδικό προστατικό Αντιγόνο:  Συγκέντρωση μάζας:  Χρονική στιγμή:  Ορός/​Πλάσμα:  Ποσοτική:  Ειδικό προστατικό Αντιγόνο:  Συγκέντρωση μάζας:  Χρονική στιγμή:  Ορός/​Πλάσμα:  Ποσοτική:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Prostatico specifico , Ag:  MCnc:  Pt:  Siero/​Plasma:  Qn:  Prostatico specifico , Ag:  MCnc:  Pt:  Siero/​Plasma:  Qn:  Prostatico specifico , Ag:  MCnc:  Pt:  Siero/​Plasma:  Qn:  
  Italian (SWITZERLAND)  (From: CUMUL, Switzerland)
 
  S--prostata, antigene specificoS--prostata, antigene specificoS--prostata, antigene specifico
  Korean (KOREA, REPUBLIC OF)  (From: Korean Ministry for Health, Welfare, and Family Affairs)
 
  전립선 특이 항원:  질량농도:  검사시점:  혈청/​혈장:  정량:  전립선 특이 항원:  질량농도:  검사시점:  혈청/​혈장:  정량:  전립선 특이 항원:  질량농도:  검사시점:  혈청/​혈장:  정량:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  PSA SerPl-mCncProstático Específico Ag:  MCnc:  Pt:  Sor/​Plas:  Qn:  Prostático Específico Ag:  MCnc:  Pt:  Sor/​Plas:  Qn:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Простат специфический Аг:  МассКонц:  ТчкВрм:  Сыв/​Плаз:  Колич:  Простат специфический Аг:  МассКонц:  ТчкВрм:  Сыв/​Плаз:  Колич:  Простат специфический Аг:  МассКонц:  ТчкВрм:  Сыв/​Плаз:  Колич:  
  Spanish (ARGENTINA)  (From: Conceptum Medical Terminology Center)
 
  [antígeno] prostático específico [Ag]:concentración de masa:punto en el tiempo:suero:cuantitativo:[antígeno] prostático específico [Ag]:  concentración de masa:  punto en el tiempo:  suero:  cuantitativo:  [antígeno] prostático específico [Ag]:  concentración de masa:  punto en el tiempo:  suero:  cuantitativo:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Prostático específico Ag:  Concentración de masa:  Punto temporal:  Suero o Plasma:  Qn:  Prostático específico Ag:  Concentración de masa:  Punto temporal:  Suero o Plasma:  Qn:  Prostático específico Ag:  Concentración de masa:  Punto temporal:  Suero o Plasma:  Qn:  
  Spanish (SWITZERLAND)  (From: CUMUL, Switzerland)
 
  S--próstata, antígeno especificoS--próstata, antígeno especificoS--próstata, antígeno especifico
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Prostat spesifik Ag:  KütlKons:  Zmlı:  Ser/​Plaz:  Kant:  Prostat spesifik Ag:  KütlKons:  Zmlı:  Ser/​Plaz:  Kant:  Prostat spesifik Ag:  KütlKons:  Zmlı:  Ser/​Plaz:  Kant:  

RELATED NAMES
  Antigen Plsm Seminin
  Antigens Point in time SerP
  Chemistry PS SerPl
  Kallikrein 3 PSA SerPlas
  Level QNT Serum
  Mass concentration Quan Serum or plasma
  P-30 antigen Quant Spec
  Pl Quantitative SR
  Plasma Random  

EXAMPLE UNITS
  Unit  Source Type
  ng/mL  EXAMPLE UCUM UNITS 
  ng/mL  REGENSTRIEF 
  ug/L  eCHN 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit:  ng/mL 
  Source Type:  REGENSTRIEF 
  Unit:  ng/mL 
  Source Type:  eCHN 
  Unit:  ug/L 

UNITS AND RANGE
  Range  Units Type
  ng/mL:[0,4.0]   

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: Y
  Long Common Name: Prostate specific Ag [Mass/volume] in Serum or Plasma
  Shortname: PSA SerPl-mCnc
  Fully Specified Name: Prostate specific Ag: MCnc: Pt: Ser/Plas: Qn:
     
  Component Word Count: 3
  ID: 19763
  Status (Raw): ACTIVE


55752-0   Clinical informationClinical informationClinical information: Find: Pt: ^Patient: Nar:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Clinical information  Find  Pt  ^Patient  Nar 
  Long Common Name:  Clinical information
  Shortname:  Clinical info

TERM DEFINITION/DESCRIPTION(S)
  A section containing clinical details about the case such as presenting signs and symptoms, onset date of symptoms, the specific diagnosis/condition names (e.g Ulceroglandular tularemia), who made the diagnosis, their contact information , when the diagnosis was made etc., past clinical hx, the overall condition of the patient, etc.
 
 

BASIC ATTRIBUTES
  Class/Type: PUBLICHEALTH/Clinical
  First Released in Version: 2.27
  Last Updated in Version: 2.40
  Status: Active

MEMBER OF THESE PANELS
  81186-9   Gastric cancer pathology panelGastric cancer pathology panelCancer pathology panel: -: Pt: Stomach cancer: -:
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP94952-6  Clinical information 
Property   LP6813-2  Find   [Finding] 
Time   LP6960-1  Pt   [Point in time (spot)] 
Super System   LP6985-8  Patient 
Scale   LP7749-7  Nar 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  临床信息:  发现:  时间点:  ^患者:  叙述型:  临床信息:  发现:  时间点:  ^患者:  叙述型:  临床信息:  发现:  时间点:  ^患者:  叙述型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Informazioni cliniche:  Osservazione:  Pt:  ^Paziente:  Nar:  Informazioni cliniche:  Osservazione:  Pt:  ^Paziente:  Nar:  Informazioni cliniche:  Osservazione:  Pt:  ^Paziente:  Nar:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Клиническая информация:  Находка:  ТчкВрм:  ^Пациент:  Опис:  Клиническая информация:  Находка:  ТчкВрм:  ^Пациент:  Опис:  Клиническая информация:  Находка:  ТчкВрм:  ^Пациент:  Опис:  

RELATED NAMES
  Finding Point in time Random
  Findings Public Health Report
  Narrative PUBLICHEALTH  

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Clinical information
  Shortname: Clinical info
  Fully Specified Name: Clinical information: Find: Pt: ^Patient: Nar:
     
  Component Word Count: 2
  ID: 50197
  Status (Raw): ACTIVE


21908-9   Stage group.clinical CancerStage group.clinical CancerStage group.clinical: Class: Pt: Cancer.XXX: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Stage group.clinical  Class  Pt  Cancer.XXX  Nom 
  Long Common Name:  Stage group.clinical Cancer
  Shortname:  Stg grp.clinical Cancer

TERM DEFINITION/DESCRIPTION(S)
  Detailed site-specific codes for the clinical stage group as defined by AJCC and recorded by the physician. Pathologic, clinical, and other stage data are given three separate areas in the NAACCR Data Exchange Record Layout.

COC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results... NAACCR Data Standards and Data Dictionary Version 11
 
 

BASIC ATTRIBUTES
  Class/Type: TUMRRGT/Clinical
  First Released in Version: 1.0m
  Last Updated in Version: 2.32
  Status: Active

NORMATIVE ANSWER LIST    (LL240-3)  
 
Source: 
  SEQ#        Answer        Code         Answer ID    
  1       Stage IVB       4B       LA3649-6  
  2       Stage IVA       4A       LA3650-4  
  3       Stage IV       4       LA3651-2  
  4       Stage IIIC       3C       LA3654-6  
  5       Stage IIIB       3B       LA3655-3  
  6       Stage IIIA       3A       LA3656-1  
  7       Stage III       3       LA3657-9  
  8       Stage IIC       2C       LA3658-7  
  9       Stage IIB       2B       LA3659-5  
  10       Stage IIA       2A       LA3660-3  
  11       Stage II       2       LA3661-1  
  12       Stage IA       1A       LA3663-7  
  13       Stage I       1       LA3664-5  
  14       Stage T1A2       A2       LA4284-1  
  15       Stage IVC       4C       LA4314-6  
  16       Stage IC       1C       LA4316-1  
  17       Stage 0is       0S       LA4321-1  
  18       Stage 0A       0A       LA4322-9  
  19       Stage 0       0       LA4323-7  
  20       Stage T1B       1B       LA4371-6  
  21       Recurrent, unstaged, unknown, Stage X       99       LA4391-4  
  22       Stage T1A1       A1       LA4401-1  
  23       Stage T1B2       B2       LA4484-7  
  24       Stage T1B1       B1       LA4485-4  
  25       Not applicable (no AJCC staging scheme)       88       LA4703-0  
  26       Occult       OC       LA4744-4  
  27       Stage IE       1E       LA21791-1  
  28       Stage IS       1S       LA4315-3  
  29       Stage IIA1       2A1       LA21844-8  
  30       Stage IIA2       2A2       LA21845-5  
  31       Stage IIE       2E       LA21794-5  
  32       Stage IIS       2S       LA21847-1  
  33       Stage IIIC1       3C1       LA21848-9  
  34       Stage IIIC2       3C2       LA21871-1  
  35       Stage IIIE       3E       LA3652-0  
  36       Stage IIIS       3S       LA21800-0  
  37       Stage IVA1       4A1       LA21872-9  
  38       Stage IVA2       4A2       LA21850-5  
  39       Stage IVE       4E       LA21802-6  
  40       Stage IVS       4S       LA3648-8  

MEMBER OF THESE PANELS
  49083-9   North American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 11 panelNorth American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 11 panelNorth American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 11 panel: -: Pt: ^Patient: -:
  59852-4   North American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 12 panelNorth American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 12 panelNorth American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 12 panel: -: Pt: ^Patient: -:
  75620-5   TNM clinical staging before treatment panel CancerTNM clinical staging before treatment panel CancerTNM clinical staging before treatment panel: -: Pt: Cancer.XXX: -:
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP73397-9  Stage group.clinical 
Property   LP6795-1  Class 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP7102-9  Cancer.XXX   [Cancer XXX] 
Scale   LP7750-5  Nom 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  期别.临床:  分类:  时间点:  癌.XXX:  名义型:  期别.临床:  分类:  时间点:  癌.XXX:  名义型:  期别.临床:  分类:  时间点:  癌.XXX:  名义型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Stadio, gruppo.clinico:  Classe:  Pt:  Cancro.XXX:  Nom:  Stadio, gruppo.clinico:  Classe:  Pt:  Cancro.XXX:  Nom:  Stadio, gruppo.clinico:  Classe:  Pt:  Cancro.XXX:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Стадия группа.клинический:  Класс:  ТчкВрм:  Рак.XXX:  Ном:  Стадия группа.клинический:  Класс:  ТчкВрм:  Рак.XXX:  Ном:  Стадия группа.клинический:  Класс:  ТчкВрм:  Рак.XXX:  Ном:  
  Spanish (ARGENTINA)  (From: Conceptum Medical Terminology Center)
 
  grupo de estadio.clínico:clase:punto en el tiempo:cáncer.XXX:Nominal:grupo de estadio.clínico:  clase:  punto en el tiempo:  cáncer.XXX:  Nominal:  grupo de estadio.clínico:  clase:  punto en el tiempo:  cáncer.XXX:  Nominal:  

RELATED NAMES
  CA Other To be specified in another part of the message
  Misc Point in time TUMOR REGISTRY(NAACCR)
  Miscellaneous Random Unspecified
  Nominal Stg grp.clinical  

ALTERNATIVE CODES
  NAACCR_ID:  970 

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Long Common Name: Stage group.clinical Cancer
  Shortname: Stg grp.clinical Cancer
  Fully Specified Name: Stage group.clinical: Class: Pt: Cancer.XXX: Nom:
     
  Component Word Count: 3
  ID: 13012
  Status (Raw): ACTIVE


33723-8   Specimen lengthSpecimen lengthSpecimen length: Len: Pt: Specimen: Qn:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Specimen length  Len  Pt  Specimen  Qn 
  Long Common Name:  Specimen length
  Shortname:  Specimen length

BASIC ATTRIBUTES
  Class/Type: PATH.PROTOCOLS.GENER/Lab
  First Released in Version: 2.09
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Removed Method since this term is not specific to CAP cancer protocols.

SUBMITTER'S INFORMATION
  Submitted Units: cm

MEMBER OF THESE PANELS
  84907-5   Cancer pathology panel - Colorectal cancer specimenCancer pathology panel - Colorectal cancer specimenCancer pathology panel: -: Pt: Colorectal cancer specimen: -:
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP73377-1  Specimen length 
Property   LP6822-3  Len   [Length] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP7593-9  Specimen 
Scale   LP7753-9  Qn 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  标本长度:  长度:  时间点:  标本:  定量型:  标本长度:  长度:  时间点:  标本:  定量型:  标本长度:  长度:  时间点:  标本:  定量型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Monsterlengte:  Lengte:  Moment:  Monster:  Kwantitatief:  Monsterlengte:  Lengte:  Moment:  Monster:  Kwantitatief:  Monsterlengte:  Lengte:  Moment:  Monster:  Kwantitatief:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Campione, lunghezza:  Len:  Pt:  Campione:  Qn:  Campione, lunghezza:  Len:  Pt:  Campione:  Qn:  Campione, lunghezza:  Len:  Pt:  Campione:  Qn:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Specimen length Spec CAP protocolComprimento da amostra:  Comprimento:  Pt:  Amostra:  Qn:  Protocolos de cancer do CAPComprimento da amostra:  Comprimento:  Pt:  Amostra:  Qn:  Protocolos de cancer do CAP
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Образец длина:  Дл:  ТчкВрм:  Образец:  Колич:  Образец длина:  Дл:  ТчкВрм:  Образец:  Колич:  Образец длина:  Дл:  ТчкВрм:  Образец:  Колич:  
  Spanish (ARGENTINA)  (From: Conceptum Medical Terminology Center)
 
  largo de espécimen:longitud:punto en el tiempo:espécimen:cuantitativo:protocolos de oncología del CAPlargo de espécimen:  longitud:  punto en el tiempo:  espécimen:  cuantitativo:  protocolos de oncología del CAPlargo de espécimen:  longitud:  punto en el tiempo:  espécimen:  cuantitativo:  protocolos de oncología del CAP
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Longitud del especimen:  Longitud:  Punto temporal:  Espécimen:  Qn:  Longitud del especimen:  Longitud:  Punto temporal:  Espécimen:  Qn:  Longitud del especimen:  Longitud:  Punto temporal:  Espécimen:  Qn:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Örnek uzunluğu:  Uzn:  Zmlı:  Örnek:  Kant:  Örnek uzunluğu:  Uzn:  Zmlı:  Örnek:  Kant:  Örnek uzunluğu:  Uzn:  Zmlı:  Örnek:  Kant:  

RELATED NAMES
  Len Point in time Random
  Length QNT Spec
  Pathology Quan  
  PATHOLOGY PROTOCOLS Quant  
  PATHOLOGY PROTOCOLS general Quantitative  

EXAMPLE UNITS
  Unit  Source Type
  cm  EXAMPLE UCUM UNITS 
  cm  ORIGINAL SUBMISSION 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit:  cm 
  Source Type:  ORIGINAL SUBMISSION 
  Unit:  cm 

CHANGE HISTORY
  Change Type: MAJ

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Specimen length
  Shortname: Specimen length
  Fully Specified Name: Specimen length: Len: Pt: Specimen: Qn:
     
  Component Word Count: 2
  ID: 25969
  Status (Raw): ACTIVE


84894-5   Dimension [Length] of SpecimenDimension [Length] of SpecimenDimension: Len: Pt: Specimen: Qn:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Dimension  Len  Pt  Specimen  Qn 
  Long Common Name:  Dimension [Length] of Specimen
  Shortname:  Dimension Spec

TERM DEFINITION/DESCRIPTION(S)
  The size of a specimen may be recorded in two or more linear measurements (dimensions), e.g. length and width. Each dimension can be recorded by repeating this term. Specimen dimensions enable comparison with clinical and imaging estimates of volume. To record only the length of a specimen, use "Specimen length" [LOINC: 33723-8] . This term was created for, but not limited in use to, the Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol (2nd Edition, 2014) developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP238882-7  Dimension 
Property   LP6822-3  Len   [Length] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP7593-9  Specimen 
Scale   LP7753-9  Qn 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  尺寸:  长度:  时间点:  标本:  定量型:  尺寸:  长度:  时间点:  标本:  定量型:  尺寸:  长度:  时间点:  标本:  定量型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Dimensión:  Longitud:  Punto temporal:  Espécimen:  Qn:  Dimensión:  Longitud:  Punto temporal:  Espécimen:  Qn:  Dimensión:  Longitud:  Punto temporal:  Espécimen:  Qn:  

RELATED NAMES
  Length QNT Quantitative
  Pathology Quan Random
  Point in time Quant Spec

EXAMPLE UNITS
  Unit  Source Type
  mm  EXAMPLE UCUM UNITS 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit:  mm 

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Dimension [Length] of Specimen
  Shortname: Dimension Spec
  Fully Specified Name: Dimension: Len: Pt: Specimen: Qn:
     
  Component Word Count: 0
  ID: 90064
  Status (Raw): TRIAL


84895-2   Seminal vesicles [Presence] in SpecimenSeminal vesicles [Presence] in SpecimenSeminal vesicles: PrThr: Pt: Specimen: Ord:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Seminal vesicles  PrThr  Pt  Specimen  Ord 
  Long Common Name:  Seminal vesicles [Presence] in Specimen
  Shortname:  Seminal vesicles Spec Ql

TERM DEFINITION/DESCRIPTION(S)
  The presence (partially or completely resected) or absence of seminal vesicles in the specimen. This term was created for, but not limited in use to, the Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol (2nd Edition, 2014) developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

EXAMPLE ANSWER LIST    (LL3950-4)  
 
Source: Regenstrief LOINC
  SEQ#        Answer        Answer ID    
  1       Present
SNOMEDCT ©: 52101004 Present (qualifier value)    
  LA9633-4  
  2       Absent       LA9634-2  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP222098-8  Seminal vesicles 
Property   LP217195-9  PrThr   [Presence or Threshold] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP7593-9  Specimen 
Scale   LP7751-3  Ord 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  精囊:  存在情况或阈值:  时间点:  标本:  序数型:  精囊:  存在情况或阈值:  时间点:  标本:  序数型:  精囊:  存在情况或阈值:  时间点:  标本:  序数型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Vesículas seminales:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Espécimen:  Ord:  Vesículas seminales:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Espécimen:  Ord:  Vesículas seminales:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Espécimen:  Ord:  

RELATED NAMES
  Ordinal QL Screen
  PATHOLOGY Qual Spec
  Point in time Qualitative  
  PR Random  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Seminal vesicles [Presence] in Specimen
  Shortname: Seminal vesicles Spec Ql
  Fully Specified Name: Seminal vesicles: PrThr: Pt: Specimen: Ord:
     
  Component Word Count: 0
  ID: 90065
  Status (Raw): TRIAL


84896-0   Lymph node(s) [Presence] in SpecimenLymph node(s) [Presence] in SpecimenLymph node(s): PrThr: Pt: Specimen: Ord:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Lymph node(s)  PrThr  Pt  Specimen  Ord 
  Long Common Name:  Lymph node(s) [Presence] in Specimen
  Shortname:  Lymph node(s) Spec Ql

TERM DEFINITION/DESCRIPTION(S)
  The presence or absence of lymph nodes in the specimen. This term was created for, but not limited in use to, the Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol (2nd Edition, 2014) developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

EXAMPLE ANSWER LIST    (LL3950-4)  
 
Source: Regenstrief LOINC
  SEQ#        Answer        Answer ID    
  1       Present
SNOMEDCT ©: 52101004 Present (qualifier value)    
  LA9633-4  
  2       Absent       LA9634-2  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP238883-5  Lymph node(s) 
Property   LP217195-9  PrThr   [Presence or Threshold] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP7593-9  Specimen 
Scale   LP7751-3  Ord 
Fragments for synonyms   LP75926-3  S' 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  淋巴结:  存在情况或阈值:  时间点:  标本:  序数型:  淋巴结:  存在情况或阈值:  时间点:  标本:  序数型:  淋巴结:  存在情况或阈值:  时间点:  标本:  序数型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Nódulo(s) linfático(s):  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Espécimen:  Ord:  Nódulo(s) linfático(s):  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Espécimen:  Ord:  Nódulo(s) linfático(s):  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Espécimen:  Ord:  

RELATED NAMES
  LN QL Screen
  Ordinal Qual Spec
  Pathology Qualitative  
  Point in time Random  
  PR S prime  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Lymph node(s) [Presence] in Specimen
  Shortname: Lymph node(s) Spec Ql
  Fully Specified Name: Lymph node(s): PrThr: Pt: Specimen: Ord:
     
  Component Word Count: 0
  ID: 90066
  Status (Raw): TRIAL


84897-8   Dominant nodule quadrant [Anatomy] in Prostate tumorDominant nodule quadrant [Anatomy] in Prostate tumorDominant nodule quadrant: Anat: Pt: Prostate tumor: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Dominant nodule quadrant  Anat  Pt  Prostate tumor  Nom 
  Long Common Name:  Dominant nodule quadrant [Anatomy] in Prostate tumor
  Shortname:  Dominant nodule quad PrT

TERM DEFINITION/DESCRIPTION(S)
  The quadrant (e.g. right anterior, right posterior, left anterior or left posterior) in which the dominant (largest) nodule of the tumor is located. To record the quadrant in which the other nodule(s) are located, use [LOINC: 84900-0] . This term was created for, but not limited in use to, the Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol (2nd Edition, 2014) developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

PREFERRED ANSWER LIST    (LL4079-1)  
 
Source: The Royal College of Pathologists of Australasia
  SEQ#        Answer        Answer ID    
  1       Right anterior       LA26548-0  
  2       Left anterior       LA26550-6  
  3       Right posterior       LA26549-8  
  4       Left posterior       LA26551-4  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP222099-6  Dominant nodule quadrant 
Property   LP6777-9  Anat   [Anatomy] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7750-5  Nom 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  优势结节象限:  解剖学:  时间点:  前列腺肿瘤:  名义型:  优势结节象限:  解剖学:  时间点:  前列腺肿瘤:  名义型:  优势结节象限:  解剖学:  时间点:  前列腺肿瘤:  名义型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Cuadrante del nódulo dominante:  Anat:  Punto temporal:  Tumor prostático:  Nom:  Cuadrante del nódulo dominante:  Anat:  Punto temporal:  Tumor prostático:  Nom:  Cuadrante del nódulo dominante:  Anat:  Punto temporal:  Tumor prostático:  Nom:  

RELATED NAMES
  Anatomy Prost tumour
  Cancer Prostatic tumours
  Nominal PrT  
  Pathology Random  
  Point in time tumors  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Dominant nodule quadrant [Anatomy] in Prostate tumor
  Shortname: Dominant nodule quad PrT
  Fully Specified Name: Dominant nodule quadrant: Anat: Pt: Prostate tumor: Nom:
     
  Component Word Count: 0
  ID: 90067
  Status (Raw): TRIAL


84898-6   Dominant nodule plane [Anatomy] in Prostate tumorDominant nodule plane [Anatomy] in Prostate tumorDominant nodule plane: Anat: Pt: Prostate tumor: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Dominant nodule plane  Anat  Pt  Prostate tumor  Nom 
  Long Common Name:  Dominant nodule plane [Anatomy] in Prostate tumor
  Shortname:  Dominant nodule plane PrT

TERM DEFINITION/DESCRIPTION(S)
  The location of the dominant (largest) nodule by plane (e.g. apex, mid, or base of prostate). This information is important for correlation with needle biopsy findings, imaging results, etc. To record the location of other nodule(s) by plane, use [LOINC: 84901-8] . This term was created for, but not limited in use to, the Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol (2nd Edition, 2014) developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

PREFERRED ANSWER LIST    (LL4080-9)  
 
Source: The Royal College of Pathologists of Australasia
  SEQ#        Answer        Answer ID    
  1       Apex       LA25154-8  
  2       Mid       LA26546-4  
  3       Base       LA25152-2  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP222100-2  Dominant nodule plane 
Property   LP6777-9  Anat   [Anatomy] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7750-5  Nom 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  优势结节平面:  解剖学:  时间点:  前列腺肿瘤:  名义型:  优势结节平面:  解剖学:  时间点:  前列腺肿瘤:  名义型:  优势结节平面:  解剖学:  时间点:  前列腺肿瘤:  名义型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Plano del nódulo dominate:  Anat:  Punto temporal:  Tumor prostático:  Nom:  Plano del nódulo dominate:  Anat:  Punto temporal:  Tumor prostático:  Nom:  Plano del nódulo dominate:  Anat:  Punto temporal:  Tumor prostático:  Nom:  

RELATED NAMES
  Anatomy Prost tumour
  Cancer Prostatic tumours
  Nominal PrT  
  Pathology Random  
  Point in time tumors  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Dominant nodule plane [Anatomy] in Prostate tumor
  Shortname: Dominant nodule plane PrT
  Fully Specified Name: Dominant nodule plane: Anat: Pt: Prostate tumor: Nom:
     
  Component Word Count: 0
  ID: 90068
  Status (Raw): TRIAL


84899-4   Other nodules greater than 10mm in diameter [Presence] in Prostate tumorOther nodules greater than 10mm in diameter [Presence] in Prostate tumorOther nodules greater than 10mm in diameter: PrThr: Pt: Prostate tumor: Ord:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Other nodules greater than 10mm in diameter  PrThr  Pt  Prostate tumor  Ord 
  Long Common Name:  Other nodules greater than 10mm in diameter [Presence] in Prostate tumor
  Shortname:  Other nodules >10mm diameter PrT Ql

TERM DEFINITION/DESCRIPTION(S)
  The presence or absence of other nodules greater than 10 mm in diameter in addition to the dominant (largest) nodule in the prostate tumor. This term was created for, but not limited in use to, the Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol (2nd Edition, 2014) developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

EXAMPLE ANSWER LIST    (LL3950-4)  
 
Source: Regenstrief LOINC
  SEQ#        Answer        Answer ID    
  1       Present
SNOMEDCT ©: 52101004 Present (qualifier value)    
  LA9633-4  
  2       Absent       LA9634-2  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP222102-8  Other nodules greater than 10mm in diameter 
Property   LP217195-9  PrThr   [Presence or Threshold] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7751-3  Ord 
Fragments for synonyms   LP21049-9  Other 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  直径大于 10mm 的其他结节:  存在情况或阈值:  时间点:  前列腺肿瘤:  序数型:  直径大于 10mm 的其他结节:  存在情况或阈值:  时间点:  前列腺肿瘤:  序数型:  直径大于 10mm 的其他结节:  存在情况或阈值:  时间点:  前列腺肿瘤:  序数型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Otros nódulos mayores de 10 mm de diámetro:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Tumor prostático:  Ord:  Otros nódulos mayores de 10 mm de diámetro:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Tumor prostático:  Ord:  Otros nódulos mayores de 10 mm de diámetro:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Tumor prostático:  Ord:  

RELATED NAMES
  10mm diameter Pathology Qualitative
  Cancer Point in time Random
  DIA PR Screen
  Diam Prost tumors
  Ordinal Prostatic tumour
  Other nodules &gt QL tumours
  Othr Qual  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Other nodules greater than 10mm in diameter [Presence] in Prostate tumor
  Shortname: Other nodules >10mm diameter PrT Ql
  Fully Specified Name: Other nodules greater than 10mm in diameter: PrThr: Pt: Prostate tumor: Ord:
     
  Component Word Count: 0
  ID: 90069
  Status (Raw): TRIAL


84900-0   Other nodule quadrant [Anatomy] in Prostate tumorOther nodule quadrant [Anatomy] in Prostate tumorOther nodule quadrant: Anat: Pt: Prostate tumor: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Other nodule quadrant  Anat  Pt  Prostate tumor  Nom 
  Long Common Name:  Other nodule quadrant [Anatomy] in Prostate tumor
  Shortname:  Nodule quad PrT

TERM DEFINITION/DESCRIPTION(S)
  The quadrant (e.g. right anterior, right posterior, left anterior or left posterior) in which the other nodule(s) are located. To record the quadrant location of the dominant (largest) nodule, use [LOINC: 84897-8] . This term was created for, but not limited in use to, the Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol (2nd Edition, 2014) developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

PREFERRED ANSWER LIST    (LL4079-1)  
 
Source: The Royal College of Pathologists of Australasia
  SEQ#        Answer        Answer ID    
  1       Right anterior       LA26548-0  
  2       Left anterior       LA26550-6  
  3       Right posterior       LA26549-8  
  4       Left posterior       LA26551-4  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP222108-5  Other nodule quadrant 
Property   LP6777-9  Anat   [Anatomy] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7750-5  Nom 
Fragments for synonyms   LP21049-9  Other 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  其他结节象限:  解剖学:  时间点:  前列腺肿瘤:  名义型:  其他结节象限:  解剖学:  时间点:  前列腺肿瘤:  名义型:  其他结节象限:  解剖学:  时间点:  前列腺肿瘤:  名义型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Cuadrante de otro nódulo:  Anat:  Punto temporal:  Tumor prostático:  Nom:  Cuadrante de otro nódulo:  Anat:  Punto temporal:  Tumor prostático:  Nom:  Cuadrante de otro nódulo:  Anat:  Punto temporal:  Tumor prostático:  Nom:  

RELATED NAMES
  Anatomy Point in time tumors
  Cancer Prost tumour
  Nominal Prostatic tumours
  Othr PrT  
  Pathology Random  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Other nodule quadrant [Anatomy] in Prostate tumor
  Shortname: Nodule quad PrT
  Fully Specified Name: Other nodule quadrant: Anat: Pt: Prostate tumor: Nom:
     
  Component Word Count: 0
  ID: 90070
  Status (Raw): TRIAL


84901-8   Other nodule plane [Anatomy] in Prostate tumorOther nodule plane [Anatomy] in Prostate tumorOther nodule plane: Anat: Pt: Prostate tumor: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Other nodule plane  Anat  Pt  Prostate tumor  Nom 
  Long Common Name:  Other nodule plane [Anatomy] in Prostate tumor
  Shortname:  Other nodule plane PrT

TERM DEFINITION/DESCRIPTION(S)
  The location of the other nodule(s) by plane (e.g. apex, mid, or base of prostate). To record the plane location of the dominant (largest) nodule, use [LOINC: 84898-6] . This term was created for, but not limited in use to, the Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol (2nd Edition, 2014) developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

PREFERRED ANSWER LIST    (LL4080-9)  
 
Source: The Royal College of Pathologists of Australasia
  SEQ#        Answer        Answer ID    
  1       Apex       LA25154-8  
  2       Mid       LA26546-4  
  3       Base       LA25152-2  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP222101-0  Other nodule plane 
Property   LP6777-9  Anat   [Anatomy] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7750-5  Nom 
Fragments for synonyms   LP21049-9  Other 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  其他结节平面:  解剖学:  时间点:  前列腺肿瘤:  名义型:  其他结节平面:  解剖学:  时间点:  前列腺肿瘤:  名义型:  其他结节平面:  解剖学:  时间点:  前列腺肿瘤:  名义型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Plano de otro nódulo:  Anat:  Punto temporal:  Tumor prostático:  Nom:  Plano de otro nódulo:  Anat:  Punto temporal:  Tumor prostático:  Nom:  Plano de otro nódulo:  Anat:  Punto temporal:  Tumor prostático:  Nom:  

RELATED NAMES
  Anatomy Point in time tumors
  Cancer Prost tumour
  Nominal Prostatic tumours
  Othr PrT  
  Pathology Random  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Other nodule plane [Anatomy] in Prostate tumor
  Shortname: Other nodule plane PrT
  Fully Specified Name: Other nodule plane: Anat: Pt: Prostate tumor: Nom:
     
  Component Word Count: 0
  ID: 90071
  Status (Raw): TRIAL


44657-5   Dominant nodule.maximum.dimension in Prostate tumorDominant nodule.maximum.dimension in Prostate tumorDominant nodule.max.dimension: Len: Pt: Prostate tumor: Qn:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Dominant nodule.max.dimension  Len  Pt  Prostate tumor  Qn 
  Long Common Name:  Dominant nodule.maximum.dimension in Prostate tumor
  Shortname:  Dom nodule.max.dim PrT

BASIC ATTRIBUTES
  Class/Type: PATH.PROTOCOLS.PROST/Lab
  First Released in Version: 2.17
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Removed method of "CAP cancer protocols" because this term is not a CAP cancer protocol-specific concept and can be used across various cancer protocols.

SUBMITTER'S INFORMATION
  Submitted Units: cm

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP72489-5  Dominant nodule.max.dimension 
Property   LP6822-3  Len   [Length] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7753-9  Qn 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  优势结节.最大值.维度:  长度:  时间点:  前列腺肿瘤:  定量型:  优势结节.最大值.维度:  长度:  时间点:  前列腺肿瘤:  定量型:  优势结节.最大值.维度:  长度:  时间点:  前列腺肿瘤:  定量型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Dominante nodus.max.dimensie:  Lengte:  Moment:  Prostaattumor:  Kwantitatief:  Dominante nodus.max.dimensie:  Lengte:  Moment:  Prostaattumor:  Kwantitatief:  Dominante nodus.max.dimensie:  Lengte:  Moment:  Prostaattumor:  Kwantitatief:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Nodulo dominante.massima.dimensione:  Len:  Pt:  Tumore della prostata:  Qn:  Nodulo dominante.massima.dimensione:  Len:  Pt:  Tumore della prostata:  Qn:  Nodulo dominante.massima.dimensione:  Len:  Pt:  Tumore della prostata:  Qn:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Dom nodule.max.dim Prostate Tumor CAP prNódulo dominante.dimensão máxima:  Comprimento:  Pt:  Tumor de próstata:  Qn:  Protocolos de cancer do CAPNódulo dominante.dimensão máxima:  Comprimento:  Pt:  Tumor de próstata:  Qn:  Protocolos de cancer do CAP
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Доминирующий узел.max.измерение:  Дл:  ТчкВрм:  Простата опухоль:  Колич:  Доминирующий узел.max.измерение:  Дл:  ТчкВрм:  Простата опухоль:  Колич:  Доминирующий узел.max.измерение:  Дл:  ТчкВрм:  Простата опухоль:  Колич:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Nódulo dominate.dimensión máxima:  Longitud:  Punto temporal:  Tumor prostático:  Qn:  Nódulo dominate.dimensión máxima:  Longitud:  Punto temporal:  Tumor prostático:  Qn:  Nódulo dominate.dimensión máxima:  Longitud:  Punto temporal:  Tumor prostático:  Qn:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Dominant nodül.maks.boyut:  Uzn:  Zmlı:  Prostat tümörü:  Kant:  Dominant nodül.maks.boyut:  Uzn:  Zmlı:  Prostat tümörü:  Kant:  Dominant nodül.maks.boyut:  Uzn:  Zmlı:  Prostat tümörü:  Kant:  

RELATED NAMES
  Cancer PATHOLOGY PROTOCOLS PROSTATE Quant
  Dom nodule.max.dim Peak Quantitative
  Largest Point in time Random
  Length Prost tumors
  Maximal Prostatic tumour
  Maximum PrT tumours
  Pathology QNT  
  PATHOLOGY PROTOCOLS Quan  

EXAMPLE UNITS
  Unit  Source Type
  cm  EXAMPLE UCUM UNITS 
  cm  ORIGINAL SUBMISSION 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit:  cm 
  Source Type:  ORIGINAL SUBMISSION 
  Unit:  cm 

CHANGE HISTORY
  Change Type: MAJ

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Dominant nodule.maximum.dimension in Prostate tumor
  Shortname: Dom nodule.max.dim PrT
  Fully Specified Name: Dominant nodule.max.dimension: Len: Pt: Prostate tumor: Qn:
     
  Component Word Count: 4
  ID: 37900
  Status (Raw): ACTIVE


44654-2   Tissue involved by tumor in Prostate tumorTissue involved by tumor in Prostate tumorProstatic tissue involved by tumor: NFr: Pt: Prostate tumor: Qn:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Prostatic tissue involved by tumor  NFr  Pt  Prostate tumor  Qn 
  Long Common Name:  Tissue involved by tumor in Prostate tumor
  Shortname:  Tissue involved by tumor PrT

BASIC ATTRIBUTES
  Class/Type: PATH.PROTOCOLS.PROST/Lab
  First Released in Version: 2.17
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Removed method of "CAP cancer protocols" because this term is not a CAP cancer protocol-specific concept and can be used across various cancer protocols.

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP73198-1  Prostatic tissue involved by tumor 
Property   LP6838-9  NFr   [Number Fraction] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7753-9  Qn 
Fragments for synonyms   LP28481-7  Prostatic 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  肿瘤所累及的前列腺组织:  计数型分数:  时间点:  前列腺肿瘤:  定量型:  肿瘤所累及的前列腺组织:  计数型分数:  时间点:  前列腺肿瘤:  定量型:  肿瘤所累及的前列腺组织:  计数型分数:  时间点:  前列腺肿瘤:  定量型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Prostaatweefsel betrokken bij tumor:  Getalsfractie:  Moment:  Prostaattumor:  Kwantitatief:  Prostaatweefsel betrokken bij tumor:  Getalsfractie:  Moment:  Prostaattumor:  Kwantitatief:  Prostaatweefsel betrokken bij tumor:  Getalsfractie:  Moment:  Prostaattumor:  Kwantitatief:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Tessuto prostatico interessato da tumore:  NFr:  Pt:  Tumore della prostata:  Qn:  Tessuto prostatico interessato da tumore:  NFr:  Pt:  Tumore della prostata:  Qn:  Tessuto prostatico interessato da tumore:  NFr:  Pt:  Tumore della prostata:  Qn:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Tecue involved by tumor Fr Prostate TumTecidos prostáticos envolvidos por tumor:  NFr:  Pt:  Tumor de próstata:  Qn:  Protocolos de cancer do CAPTecidos prostáticos envolvidos por tumor:  NFr:  Pt:  Tumor de próstata:  Qn:  Protocolos de cancer do CAP
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Простата ткань затронутая опухолью:  КолДоля:  ТчкВрм:  Простата опухоль:  Колич:  Простата ткань затронутая опухолью:  КолДоля:  ТчкВрм:  Простата опухоль:  Колич:  Простата ткань затронутая опухолью:  КолДоля:  ТчкВрм:  Простата опухоль:  Колич:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Tejido prostático involucrado en tumor:  Fracción numérica:  Punto temporal:  Tumor prostático:  Qn:  Tejido prostático involucrado en tumor:  Fracción numérica:  Punto temporal:  Tumor prostático:  Qn:  Tejido prostático involucrado en tumor:  Fracción numérica:  Punto temporal:  Tumor prostático:  Qn:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Prostatik doku tümörün bulunduğu:  SayFr:  Zmlı:  Prostat tümörü:  Kant:  Prostatik doku tümörün bulunduğu:  SayFr:  Zmlı:  Prostat tümörü:  Kant:  Prostatik doku tümörün bulunduğu:  SayFr:  Zmlı:  Prostat tümörü:  Kant:  

RELATED NAMES
  Cancer Prost Quantitative
  Intraglandular extent Prostate Random
  Number fraction Prostati tumors
  PATHOLOGY Prostatic tumour
  PATHOLOGY PROTOCOLS PrT tumours
  PATHOLOGY PROTOCOLS PROSTATE QNT  
  Percent Quan  
  Point in time Quant  

EXAMPLE UNITS
  Unit  Source Type
  EXAMPLE UCUM UNITS 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit: 

CHANGE HISTORY
  Change Type: MAJ

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Tissue involved by tumor in Prostate tumor
  Shortname: Tissue involved by tumor PrT
  Fully Specified Name: Prostatic tissue involved by tumor: NFr: Pt: Prostate tumor: Qn:
     
  Component Word Count: 5
  ID: 37897
  Status (Raw): ACTIVE


35266-6   Gleason score in Specimen QualitativeGleason score in Specimen QualitativeGleason score: Score: Pt: Specimen: Ord:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Gleason score  Score  Pt  Specimen  Ord 
  Long Common Name:  Gleason score in Specimen Qualitative
  Shortname:  Gleason Score Spec Ql

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.12
  Last Updated in Version: 2.50
  Order vs. Obs.: Observation
  Status: Active

EXAMPLE ANSWERS
  2-4, 5, 6, 7, 8-10

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP33134-5  Gleason score 
Property   LP185820-0  Score 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP7593-9  Specimen 
Scale   LP7751-3  Ord 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  Gleason 评分:  评分:  时间点:  标本:  序数型:  Gleason 评分:  评分:  时间点:  标本:  序数型:  Gleason 评分:  评分:  时间点:  标本:  序数型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Gleason-score:  Score:  Moment:  Monster:  Ordinaal:  Gleason-score:  Score:  Moment:  Monster:  Ordinaal:  Gleason-score:  Score:  Moment:  Monster:  Ordinaal:  
  French (FRANCE)  (From: ASIP Santé (Agence des systèmes d'information partagés de santé))
 
  Score de Gleason:  Score:  Ponctuel:  Prélèvement:  Qualitatif:  Score de Gleason:  Score:  Ponctuel:  Prélèvement:  Qualitatif:  Score de Gleason:  Score:  Ponctuel:  Prélèvement:  Qualitatif:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Gleason, punteggio:  Punteggio:  Pt:  Campione:  Ord:  Gleason, punteggio:  Punteggio:  Pt:  Campione:  Ord:  Gleason, punteggio:  Punteggio:  Pt:  Campione:  Ord:  
  Spanish (ARGENTINA)  (From: Conceptum Medical Terminology Center)
 
  puntaje de Gleason:hallazgo:punto en el tiempo:espécimen:ordinal:puntaje de Gleason:  hallazgo:  punto en el tiempo:  espécimen:  ordinal:  puntaje de Gleason:  hallazgo:  punto en el tiempo:  espécimen:  ordinal:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Escala Gleason:  Puntuación:  Punto temporal:  Espécimen:  Ord:  Escala Gleason:  Puntuación:  Punto temporal:  Espécimen:  Ord:  Escala Gleason:  Puntuación:  Punto temporal:  Espécimen:  Ord:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Gleason skoru:  Skor:  Zmlı:  Örnek:  Srl:  Gleason skoru:  Skor:  Zmlı:  Örnek:  Srl:  Gleason skoru:  Skor:  Zmlı:  Örnek:  Srl:  

RELATED NAMES
  GS QL Scale
  Ordinal Qual Screen
  PATHOLOGY Qualitative Spec
  Point in time Random  

EXAMPLE UNITS
  Unit  Source Type
  {score}  EXAMPLE UCUM UNITS 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit:  {score} 

CHANGE HISTORY
  Change Type: MIN

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Gleason score in Specimen Qualitative
  Shortname: Gleason Score Spec Ql
  Fully Specified Name: Gleason score: Score: Pt: Specimen: Ord:
     
  Component Word Count: 2
  ID: 27661
  Status (Raw): ACTIVE


84903-4   Extraprostatic extension extent [Type] of Prostate tumorExtraprostatic extension extent [Type] of Prostate tumorExtraprostatic extension extent: Type: Pt: Prostate tumor: Ord:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Extraprostatic extension extent  Type  Pt  Prostate tumor  Ord 
  Long Common Name:  Extraprostatic extension extent [Type] of Prostate tumor
  Shortname:  EPE extent PrT Ql

TERM DEFINITION/DESCRIPTION(S)
  Categorization of the extent of extraprostatic extension (EPE) as focal or non-focal (also called established or extensive). The identification of any EPE is important since both focal and non-focal EPE are associated with a significantly higher risk of recurrence. [PMID: 9712429] This term was created for, but not limited in use to, the Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol (2nd Edition, 2014) developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

EXAMPLE ANSWER LIST    (LL4082-5)  
 
Source: The Royal College of Pathologists of Australasia
  SEQ#        Answer        Answer ID    
  1       Focal       LA26555-5  
  2       Non-focal       LA26556-3  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP222106-9  Extraprostatic extension extent 
Property   LP6886-8  Type 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7751-3  Ord 
Fragments for synonyms   LP34039-5  Extension 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  前列腺外侵犯范围:  类型:  时间点:  前列腺肿瘤:  序数型:  前列腺外侵犯范围:  类型:  时间点:  前列腺肿瘤:  序数型:  前列腺外侵犯范围:  类型:  时间点:  前列腺肿瘤:  序数型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Grado de extensión extraprostática.:  Tipo:  Punto temporal:  Tumor prostático:  Ord:  Grado de extensión extraprostática.:  Tipo:  Punto temporal:  Tumor prostático:  Ord:  Grado de extensión extraprostática.:  Tipo:  Punto temporal:  Tumor prostático:  Ord:  

RELATED NAMES
  Cancer Prostatic tumors
  EPE extent PrT tumour
  EXT Ql tumours
  Ordinal Qual Typ
  PATHOLOGY Qualitative  
  Point in time Random  
  Prost Screen  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Extraprostatic extension extent [Type] of Prostate tumor
  Shortname: EPE extent PrT Ql
  Fully Specified Name: Extraprostatic extension extent: Type: Pt: Prostate tumor: Ord:
     
  Component Word Count: 0
  ID: 90073
  Status (Raw): TRIAL


84902-6   Extraprostatic extension site [Anatomy] of Prostate tumorExtraprostatic extension site [Anatomy] of Prostate tumorExtraprostatic extension site: Anat: Pt: Prostate tumor: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Extraprostatic extension site  Anat  Pt  Prostate tumor  Nom 
  Long Common Name:  Extraprostatic extension site [Anatomy] of Prostate tumor
  Shortname:  Extraprostatic ext site PrT

TERM DEFINITION/DESCRIPTION(S)
  The location of extraprostatic extension (EPE), if present. EPE is defined as the extension of tumor beyond the confines of the gland into the periprostatic soft tissue. The locations include apical, bladder neck, anterior, lateral, postero-lateral, and posterior. This term was created for, but not limited in use to, the Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol (2nd Edition, 2014) developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

PREFERRED ANSWER LIST    (LL4081-7)  
 
Source: The Royal College of Pathologists of Australasia
  SEQ#        Answer        Answer ID    
  1       Apical       LA25151-4  
  2       Bladder neck       LA26552-2  
  3       Anterior       LA16059-0  
  4       Lateral       LA26553-0  
  5       Posterolateral       LA26554-8  
  6       Posterior       LA16060-8  
  7       Other       LA46-8  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP222230-7  Extraprostatic extension site 
Property   LP6777-9  Anat   [Anatomy] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7750-5  Nom 
Fragments for synonyms   LP34039-5  Extension 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  前列腺外侵犯部位:  解剖学:  时间点:  前列腺肿瘤:  名义型:  前列腺外侵犯部位:  解剖学:  时间点:  前列腺肿瘤:  名义型:  前列腺外侵犯部位:  解剖学:  时间点:  前列腺肿瘤:  名义型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Lugar de extensión extraprostática:  Anat:  Punto temporal:  Tumor prostático:  Nom:  Lugar de extensión extraprostática:  Anat:  Punto temporal:  Tumor prostático:  Nom:  Lugar de extensión extraprostática:  Anat:  Punto temporal:  Tumor prostático:  Nom:  

RELATED NAMES
  Anatomy Pathology Random
  Cancer Point in time tumors
  EXT Prost tumour
  Extraprostatic ext site Prostatic tumours
  Nominal PrT  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Extraprostatic extension site [Anatomy] of Prostate tumor
  Shortname: Extraprostatic ext site PrT
  Fully Specified Name: Extraprostatic extension site: Anat: Pt: Prostate tumor: Nom:
     
  Component Word Count: 0
  ID: 90072
  Status (Raw): TRIAL


81168-7   Site of adjacent organ or tissue involvement Cancer specimenSite of adjacent organ or tissue involvement Cancer specimenSite of adjacent organ or tissue involvement: Anat: Pt: Cancer specimen: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Site of adjacent organ or tissue involvement  Anat  Pt  Cancer specimen  Nom 
  Long Common Name:  Site of adjacent organ or tissue involvement Cancer specimen
  Shortname:  Adj org or tiss involved Ca spec

TERM DEFINITION/DESCRIPTION(S)
  Tumor stages are based on the extent of the involvement of adjacent tissues or organs, such as skin, liver, spleen, or pancreas as well as distal spread (i.e., metastasis). This term is used to report which adjacent tissue or organ(s) the tumor has spread to from the primary organ involved.
 
 

BASIC ATTRIBUTES
  Class/Type: CLIN/Clinical
  First Released in Version: 2.56
  Last Updated in Version: 2.61
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Changed System from "Stomach cancer" to "Cancer.XXX" since this observation can be used for various cancers.; Updated System from "Cancer.XXX" to clarify that the test is performed on a cancer specimen.

EXAMPLE ANSWER LIST    (LL3943-9)  
 
Source: Mater Hospital and Health Services
  SEQ#        Answer        Answer ID    
  1       None
SNOMEDCT ©: 260413007 None (qualifier value)    
  LA137-2  
  2       Pancreas       LA4654-5  
  3       Spleen       LA26010-1  
  4       Liver       LA4584-4  
  5       Other, Specify       LA46-8  

MEMBER OF THESE PANELS
  81186-9   Gastric cancer pathology panelGastric cancer pathology panelCancer pathology panel: -: Pt: Stomach cancer: -:
  84907-5   Cancer pathology panel - Colorectal cancer specimenCancer pathology panel - Colorectal cancer specimenCancer pathology panel: -: Pt: Colorectal cancer specimen: -:
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP207804-8  Site of adjacent organ or tissue involvement 
Property   LP6777-9  Anat   [Anatomy] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP247830-5  Cancer specimen 
Scale   LP7750-5  Nom 

RELATED NAMES
  Adj org or tiss involved Ca spec Point in time
  Anatomy CLIN Random
  CA Nominal Spec

CHANGE HISTORY
  Change Type: MAJ

INTERNAL FIELDS
  Long Common Name: Site of adjacent organ or tissue involvement Cancer specimen
  Shortname: Adj org or tiss involved Ca spec
  Fully Specified Name: Site of adjacent organ or tissue involvement: Anat: Pt: Cancer specimen: Nom:
     
  Component Word Count: 0
  ID: 85237
  Status (Raw): ACTIVE


44654-2   Tissue involved by tumor in Prostate tumorTissue involved by tumor in Prostate tumorProstatic tissue involved by tumor: NFr: Pt: Prostate tumor: Qn:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Prostatic tissue involved by tumor  NFr  Pt  Prostate tumor  Qn 
  Long Common Name:  Tissue involved by tumor in Prostate tumor
  Shortname:  Tissue involved by tumor PrT

BASIC ATTRIBUTES
  Class/Type: PATH.PROTOCOLS.PROST/Lab
  First Released in Version: 2.17
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Active.
Change Reason: Removed method of "CAP cancer protocols" because this term is not a CAP cancer protocol-specific concept and can be used across various cancer protocols.

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP73198-1  Prostatic tissue involved by tumor 
Property   LP6838-9  NFr   [Number Fraction] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7753-9  Qn 
Fragments for synonyms   LP28481-7  Prostatic 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  肿瘤所累及的前列腺组织:  计数型分数:  时间点:  前列腺肿瘤:  定量型:  肿瘤所累及的前列腺组织:  计数型分数:  时间点:  前列腺肿瘤:  定量型:  肿瘤所累及的前列腺组织:  计数型分数:  时间点:  前列腺肿瘤:  定量型:  
  Dutch (NETHERLANDS)  (From: Regenstrief-generated full translation based on part translation provided by NVKC, Dutch Society for Clinical Chemistry and Laboratory Medicine, The Netherlands)
 
  Prostaatweefsel betrokken bij tumor:  Getalsfractie:  Moment:  Prostaattumor:  Kwantitatief:  Prostaatweefsel betrokken bij tumor:  Getalsfractie:  Moment:  Prostaattumor:  Kwantitatief:  Prostaatweefsel betrokken bij tumor:  Getalsfractie:  Moment:  Prostaattumor:  Kwantitatief:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Tessuto prostatico interessato da tumore:  NFr:  Pt:  Tumore della prostata:  Qn:  Tessuto prostatico interessato da tumore:  NFr:  Pt:  Tumore della prostata:  Qn:  Tessuto prostatico interessato da tumore:  NFr:  Pt:  Tumore della prostata:  Qn:  
  Portuguese (BRAZIL)  (From: HL7 Brazil Institute)
 
  Tecue involved by tumor Fr Prostate TumTecidos prostáticos envolvidos por tumor:  NFr:  Pt:  Tumor de próstata:  Qn:  Protocolos de cancer do CAPTecidos prostáticos envolvidos por tumor:  NFr:  Pt:  Tumor de próstata:  Qn:  Protocolos de cancer do CAP
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Простата ткань затронутая опухолью:  КолДоля:  ТчкВрм:  Простата опухоль:  Колич:  Простата ткань затронутая опухолью:  КолДоля:  ТчкВрм:  Простата опухоль:  Колич:  Простата ткань затронутая опухолью:  КолДоля:  ТчкВрм:  Простата опухоль:  Колич:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Tejido prostático involucrado en tumor:  Fracción numérica:  Punto temporal:  Tumor prostático:  Qn:  Tejido prostático involucrado en tumor:  Fracción numérica:  Punto temporal:  Tumor prostático:  Qn:  Tejido prostático involucrado en tumor:  Fracción numérica:  Punto temporal:  Tumor prostático:  Qn:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Prostatik doku tümörün bulunduğu:  SayFr:  Zmlı:  Prostat tümörü:  Kant:  Prostatik doku tümörün bulunduğu:  SayFr:  Zmlı:  Prostat tümörü:  Kant:  Prostatik doku tümörün bulunduğu:  SayFr:  Zmlı:  Prostat tümörü:  Kant:  

RELATED NAMES
  Cancer Prost Quantitative
  Intraglandular extent Prostate Random
  Number fraction Prostati tumors
  PATHOLOGY Prostatic tumour
  PATHOLOGY PROTOCOLS PrT tumours
  PATHOLOGY PROTOCOLS PROSTATE QNT  
  Percent Quan  
  Point in time Quant  

EXAMPLE UNITS
  Unit  Source Type
  EXAMPLE UCUM UNITS 

UNITS (INTERNAL DETAILS)
  Source Type:  EXAMPLE UCUM UNITS 
  Unit: 

CHANGE HISTORY
  Change Type: MAJ

INTERNAL FIELDS
  Attachment Units Required: N
  Long Common Name: Tissue involved by tumor in Prostate tumor
  Shortname: Tissue involved by tumor PrT
  Fully Specified Name: Prostatic tissue involved by tumor: NFr: Pt: Prostate tumor: Qn:
     
  Component Word Count: 5
  ID: 37897
  Status (Raw): ACTIVE


84904-2   Gleason score at positive margin in Prostate tumor QualitativeGleason score at positive margin in Prostate tumor QualitativeGleason score at positive margin: Score: Pt: Prostate tumor: Ord:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Gleason score at positive margin  Score  Pt  Prostate tumor  Ord 
  Long Common Name:  Gleason score at positive margin in Prostate tumor Qualitative
  Shortname:  Gleason score at pos margin PrT Ql

TERM DEFINITION/DESCRIPTION(S)
  The Gleason score of the tumor at the positive surgical margin (PSM) is a recommended element of the International Collaboration on Cancer Reporting (ICCR) dataset.(http://www.iccr-cancer.org/datasets) If there are multiple PSMs with differently scored cancers present, the highest score is recorded. The Gleason score at the PSM is a known independent predictor of biochemical recurrence and may be used in the selection of patients for adjuvant therapy. [PMID: 21992536] This term was created for, but not limited in use to, the cancer structured reporting protocols developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of various cancers.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

PREFERRED ANSWER LIST    (LL746-9)  
 
Source: Regenstrief Institute
  SEQ#        Answer        Answer ID    
  1       Grade 1       LA9629-2  
  2       Grade 2       LA9630-0  
  3       Grade 3       LA9631-8  
  4       Grade 4       LA11897-8  
  5       Grade 5       LA11898-6  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP222096-2  Gleason score at positive margin 
Property   LP185820-0  Score 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7751-3  Ord 
Fragments for synonyms   LP21065-5  Positive 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  阳性边缘处的 Gleason 评分:  评分:  时间点:  前列腺肿瘤:  序数型:  阳性边缘处的 Gleason 评分:  评分:  时间点:  前列腺肿瘤:  序数型:  阳性边缘处的 Gleason 评分:  评分:  时间点:  前列腺肿瘤:  序数型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Margen positivo del Puntaje de Gleason:  Puntuación:  Punto temporal:  Tumor prostático:  Ord:  Margen positivo del Puntaje de Gleason:  Puntuación:  Punto temporal:  Tumor prostático:  Ord:  Margen positivo del Puntaje de Gleason:  Puntuación:  Punto temporal:  Tumor prostático:  Ord:  

RELATED NAMES
  Cancer Prost Scale
  Gleason score at pos margin Prostatic Screen
  GS PrT tumors
  Ordinal Ql tumour
  PATHOLOGY Qual tumours
  Point in time Qualitative  
  Pos Random  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Gleason score at positive margin in Prostate tumor Qualitative
  Shortname: Gleason score at pos margin PrT Ql
  Fully Specified Name: Gleason score at positive margin: Score: Pt: Prostate tumor: Ord:
     
  Component Word Count: 0
  ID: 90074
  Status (Raw): TRIAL


84905-9   Margin involvement [Type] in Prostate tumorMargin involvement [Type] in Prostate tumorMargin involvement: Type: Pt: Prostate tumor: Nom:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Margin involvement  Type  Pt  Prostate tumor  Nom 
  Long Common Name:  Margin involvement [Type] in Prostate tumor
  Shortname:  Margin involved PrT

TERM DEFINITION/DESCRIPTION(S)
  The type of positive margin involvement in prostate tumor is either extraprostatic extension (EPE) or intraprostatic (capsular incision). Margin involvement associated with EPE is diagnosed when malignant glands in extraprostatic tissue are transected by the resection margin. Intraprostatic margin involvement occurs when the urologist inadvertently develops the resection margin within the plane of the prostate rather than outside the capsule. Intraprostatic with a positive surgical margin is diagnosed when malignant glands are cut across adjacent to benign prostatic glands. In these cases, the edge of the prostate in this region is left in the patient. According to the largest series published, a significantly higher recurrence rate is found in patients with CI/intraprostatic margin involvement than in patients with organ confined disease with negative margins, or focal EPE with negative margins, although CI has a significantly better outcome than that associated with non-focal EPE and positive margins. [PMID: 17698141] This term was created for, but not limited in use to, the Royal College of Pathologists of Australasia (RCPA) Prostate cancer structured reporting protocol, 2nd edition (2014).
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

PREFERRED ANSWER LIST    (LL4083-3)  
 
Source: The Royal College of Pathologists of Australasia
  SEQ#        Answer        Answer ID    
  1       Extraprostatic extension (EPE)       LA26558-9  
  2       Intraprostatic (capsular incision)       LA26557-1  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP95236-3  Margin involvement 
Property   LP6886-8  Type 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7750-5  Nom 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  边缘累及:  类型:  时间点:  前列腺肿瘤:  名义型:  边缘累及:  类型:  时间点:  前列腺肿瘤:  名义型:  边缘累及:  类型:  时间点:  前列腺肿瘤:  名义型:  
  Italian (ITALY)  (From: Regenstrief-generated full translation based on part translation provided by Consiglio Nazionale delle Ricerche)
 
  Coinvolgimento margini:  Tipo:  Pt:  Tumore della prostata:  Nom:  Coinvolgimento margini:  Tipo:  Pt:  Tumore della prostata:  Nom:  Coinvolgimento margini:  Tipo:  Pt:  Tumore della prostata:  Nom:  
  Russian (RUSSIAN FEDERATION)  (From: Regenstrief-generated full translation based on part translation provided by Yaroslavl State Medical Academy)
 
  Край вовлечение:  Тип:  ТчкВрм:  Простата опухоль:  Ном:  Край вовлечение:  Тип:  ТчкВрм:  Простата опухоль:  Ном:  Край вовлечение:  Тип:  ТчкВрм:  Простата опухоль:  Ном:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Márgenes involucrados:  Tipo:  Punto temporal:  Tumor prostático:  Nom:  Márgenes involucrados:  Tipo:  Punto temporal:  Tumor prostático:  Nom:  Márgenes involucrados:  Tipo:  Punto temporal:  Tumor prostático:  Nom:  
  Turkish (TURKEY)  (From: Regenstrief-generated full translation based on part translation provided by LOINC Turkish Translation Group and the Turkish Ministry of Health)
 
  Sınırla ilgili:  Tip:  Zmlı:  Prostat tümörü:  Snf:  Sınırla ilgili:  Tip:  Zmlı:  Prostat tümörü:  Snf:  Sınırla ilgili:  Tip:  Zmlı:  Prostat tümörü:  Snf:  

RELATED NAMES
  Cancer Prost tumour
  Margin involved Prostatic tumours
  Nominal PrT Typ
  Pathology Random  
  Point in time tumors  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Margin involvement [Type] in Prostate tumor
  Shortname: Margin involved PrT
  Fully Specified Name: Margin involvement: Type: Pt: Prostate tumor: Nom:
     
  Component Word Count: 0
  ID: 90075
  Status (Raw): TRIAL


84895-2   Seminal vesicles [Presence] in SpecimenSeminal vesicles [Presence] in SpecimenSeminal vesicles: PrThr: Pt: Specimen: Ord:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Seminal vesicles  PrThr  Pt  Specimen  Ord 
  Long Common Name:  Seminal vesicles [Presence] in Specimen
  Shortname:  Seminal vesicles Spec Ql

TERM DEFINITION/DESCRIPTION(S)
  The presence (partially or completely resected) or absence of seminal vesicles in the specimen. This term was created for, but not limited in use to, the Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol (2nd Edition, 2014) developed by the Royal College of Pathologists of Australasia (RCPA) for structured reporting of prostate cancer.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

EXAMPLE ANSWER LIST    (LL3950-4)  
 
Source: Regenstrief LOINC
  SEQ#        Answer        Answer ID    
  1       Present
SNOMEDCT ©: 52101004 Present (qualifier value)    
  LA9633-4  
  2       Absent       LA9634-2  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP222098-8  Seminal vesicles 
Property   LP217195-9  PrThr   [Presence or Threshold] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP7593-9  Specimen 
Scale   LP7751-3  Ord 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  精囊:  存在情况或阈值:  时间点:  标本:  序数型:  精囊:  存在情况或阈值:  时间点:  标本:  序数型:  精囊:  存在情况或阈值:  时间点:  标本:  序数型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Vesículas seminales:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Espécimen:  Ord:  Vesículas seminales:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Espécimen:  Ord:  Vesículas seminales:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Espécimen:  Ord:  

RELATED NAMES
  Ordinal QL Screen
  PATHOLOGY Qual Spec
  Point in time Qualitative  
  PR Random  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Seminal vesicles [Presence] in Specimen
  Shortname: Seminal vesicles Spec Ql
  Fully Specified Name: Seminal vesicles: PrThr: Pt: Specimen: Ord:
     
  Component Word Count: 0
  ID: 90065
  Status (Raw): TRIAL


84906-7   Bladder neck involvement of Prostate tumorBladder neck involvement of Prostate tumorBladder neck involvement: PrThr: Pt: Prostate tumor: Ord:  

NAME
  Fully-Specified Name: 
Component   Property   Time   System   Scale   Method
Bladder neck involvement  PrThr  Pt  Prostate tumor  Ord 
  Long Common Name:  Bladder neck involvement of Prostate tumor
  Shortname:  Bladder neck involved PrT Ql

TERM DEFINITION/DESCRIPTION(S)
  This term is used to record whether or not the urinary bladder neck is involved with the prostate tumor. Microscopically, invasion of the bladder neck can be identified when there are neoplastic glands within the thick smooth muscle bundles of the bladder neck in sections from the base of the prostate in the absence of associated benign prostatic glandular tissue.
 
 

BASIC ATTRIBUTES
  Class/Type: PATH/Lab
  First Released in Version: 2.58
  Last Updated in Version: 2.58
  Order vs. Obs.: Observation
  Status: Trial – caution, may change

EXAMPLE ANSWER LIST    (LL4076-7)  
 
Source: The Royal College of Pathologists of Australasia
  SEQ#        Answer        Answer ID    
  1       Involved       LA26536-5  
  2       Not involved       LA26535-7  

MEMBER OF THESE PANELS
  84908-3   Cancer pathology panel - Prostate cancerCancer pathology panel - Prostate cancerCancer pathology panel: -: Pt: Prostate cancer.XXX: -:

PARTS

Part Type    Part No.  Part Name   
Component   LP222111-9  Bladder neck involvement 
Property   LP217195-9  PrThr   [Presence or Threshold] 
Time   LP6960-1  Pt   [Point in time (spot)] 
System   LP36757-0  Prostate tumor 
Scale   LP7751-3  Ord 

LANGUAGE VARIANTS
  Chinese (CHINA)  (From: Regenstrief-generated full translation based on part translation provided by Bethune International Peace Hospital)
 
  膀胱颈累及:  存在情况或阈值:  时间点:  前列腺肿瘤:  序数型:  膀胱颈累及:  存在情况或阈值:  时间点:  前列腺肿瘤:  序数型:  膀胱颈累及:  存在情况或阈值:  时间点:  前列腺肿瘤:  序数型:  
  Spanish (SPAIN)  (From: Regenstrief-generated full translation based on part translation provided by the Clinical Laboratory Committee of SERVICIO EXTREMEÑO DE SALUD, with the support of BITAC MAP.)
 
  Afectación del cuello vesical:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Tumor prostático:  Ord:  Afectación del cuello vesical:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Tumor prostático:  Ord:  Afectación del cuello vesical:  Propiedad utilizada para términos LOINC cuyos resultados estan en escala categórica ordenada.:  Punto temporal:  Tumor prostático:  Ord:  

RELATED NAMES
  Bladder neck involved Prost Screen
  Cancer Prostatic tumors
  Ordinal QL tumour
  PATHOLOGY Qual tumours
  Point in time Qualitative  
  PR Random  

CHANGE HISTORY
  Change Type: ADD

INTERNAL FIELDS
  Long Common Name: Bladder neck involvement of Prostate tumor
  Shortname: Bladder neck involved PrT Ql
  Fully Specified Name: Bladder neck involvement: PrThr: Pt: Prostate tumor: Ord:
     
  Component Word Count: 0
  ID: 90076
  Status (Raw): TRIAL

3rd PARTY COPYRIGHT
  Code System: http://snomed.info/sct
  This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO) under license. All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. “SNOMED” and “SNOMED CT” are registered trademarks of the IHTSDO.

This material includes content from the US Edition to SNOMED CT, which is developed and maintained by the U.S. National Library of Medicine and is available to authorized UMLS Metathesaurus Licensees from the UTS Downloads site at https://uts.nlm.nih.gov.

Use of SNOMED CT content is subject to the terms and conditions set forth in the SNOMED CT Affiliate License Agreement. It is the responsibility of those implementing this product to ensure they are appropriately licensed and for more information on the license, including how to register as an Affiliate Licensee, please refer to http://www.snomed.org/snomed-ct/get-snomed-ct or info@snomed.org. This may incur a fee in SNOMED International non-Member countries.